Results 151 to 160 of about 6,071 (199)
Some of the next articles are maybe not open access.
Drugs, 1999
The humanised monoclonal antibody palivizumab has been developed for prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (RSV) in infants at high risk; RSV is the most common cause of lower respiratory tract infections in infants.
L J, Scott, H M, Lamb
+5 more sources
The humanised monoclonal antibody palivizumab has been developed for prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (RSV) in infants at high risk; RSV is the most common cause of lower respiratory tract infections in infants.
L J, Scott, H M, Lamb
+5 more sources
Cost-effectiveness of respiratory syncytial virus prophylaxis with palivizumab
Journal of Paediatrics and Child Health, 2006 Background: a monoclonal antibody, palivizumab, directed against respiratory syncytial virus (RSV) has been shown to decrease hospitalisation rates. Because of its expense, the cost-effectiveness of this agent should be determined for high-risk groups.
Petra G Buettner, Robert Norton
exaly +2 more sources
Reactions Weekly, 2018
Infektiologie Update 2018; 26. Jahrestagung der Paul-Ehrlich-Gesellschaft für Chemotherapie (PEG)
+5 more sources
Infektiologie Update 2018; 26. Jahrestagung der Paul-Ehrlich-Gesellschaft für Chemotherapie (PEG)
+5 more sources
Hospital Medicine, 1999
Respiratory syncytial virus (RSV) affects almost all children in their first 2 years of life and can cause severe or even life-threatening disease in some at-risk infants. Treatment is limited and there is currently no safe or effective vaccine. However, a new monoclonal antibody, palivizumab, reduces RSV hospitalization by 55% in at-risk groups if ...
openaire +2 more sources
Respiratory syncytial virus (RSV) affects almost all children in their first 2 years of life and can cause severe or even life-threatening disease in some at-risk infants. Treatment is limited and there is currently no safe or effective vaccine. However, a new monoclonal antibody, palivizumab, reduces RSV hospitalization by 55% in at-risk groups if ...
openaire +2 more sources
Comments on Palivizumab (Synagis)
Pediatrics, 1999Caregivers and third-party payors need additional information from the Impact study1investigators to determine the appropriate use of palivizumab (Synagis) in select premature infants with increased risk of respiratory syncytial virus (RSV)-associated hospitalization.
F W, Moler +3 more
openaire +2 more sources
Administration of Palivizumab in the NICU
Hospital Pediatrics, 2016BACKGROUND: The American Academy of Pediatrics recommends palivizumab prophylaxis against respiratory syncytial virus (RSV) for infants at high risk for severe disease within 72 hours of hospital discharge to prevent community-associated RSV.
Neika, Vendetti +5 more
openaire +2 more sources
Pediatric Infectious Disease Journal, 2015
Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract infections in infants. Palivizumab, a means of passive prophylaxis, relies on patient adherence to ensure therapeutic effectiveness. The objective of this study is to evaluate the association between adherence and the incidence of RSV-associated outcomes and to identify ...
Parco, Chan +5 more
openaire +2 more sources
Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract infections in infants. Palivizumab, a means of passive prophylaxis, relies on patient adherence to ensure therapeutic effectiveness. The objective of this study is to evaluate the association between adherence and the incidence of RSV-associated outcomes and to identify ...
Parco, Chan +5 more
openaire +2 more sources
Use of Palivizumab in Primary Practice
Pediatrics, 2012Objective: To describe the implementation of a program for the use of palivizumab in a general pediatrics office and evaluate adherence to the 2009 American Academy of Pediatrics (AAP) guidelines. Methods: Pediatricians in a large practice were ...
Keith M, Perrin, Rodolfo E, Bégué
openaire +2 more sources
Optimum Dosage Regimen of Palivizumab?
Therapeutic Drug Monitoring, 2002Palivizumab is a humanized, monoclonal antibody used to protect at-risk infants against respiratory syncytial virus (RSV) infection. The regular dosage scheme causes a low initial trough level and accumulation of the antibody after subsequent injections.
Zaaijer, Hans L. +2 more
openaire +3 more sources
Cost–effectiveness of palivizumab in infancy
Expert Review of Pharmacoeconomics & Outcomes Research, 2007Respiratory syncytial virus is the most common cause of bronchiolitis, a lower respiratory tract infection occurring in infancy. It is responsible for several rehospitalizations, substantial morbidity and occasional deaths in the UK every year. Palivizumab is a recombinant monoclonal antibody that has been shown to reduce hospitalizations in infected ...
Nicholas D, Embleton +2 more
openaire +2 more sources